ClinicalTrials.gg
CompletedNCT01207388BLASTUpdated Feb 10, 2020Results posted

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

A Phase 2 interventional study of Blinatumomab in B-cell Acute Lymphoblastic Leukemia, sponsored by Amgen Research (Munich) GmbH. Completed at 75 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-10.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing blinatumomab in Burkitt Lymphoma — 16 open to participants now, 23 under way, 8 of them phase 3. blinatumomab · Burkitt Lymphoma.

Enrollment
10th of 35
116 · median 52
Started
2010
the only one that year
Phase 2
17 of 35
8 open now
Registered
1st of 35
by date
Lead sponsor
2 of 35
Amgen Research (Munich) GmbH

Among the 35 studies testing blinatumomab in Burkitt Lymphoma, this one is the 10th largest by enrollment, is the only one that started in 2010, is one of 17 in phase 2, and was the 1st registered.

Burkitt Lymphoma

977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

16 of the 35 studies testing blinatumomab in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 130 Burkitt Lymphoma studies recruiting now, 40 (31%) set no upper age limit and 77 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing blinatumomab in Burkitt Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.

Read the detailed description

The detection of minimal residual disease (MRD) after induction therapy and/or consolidation therapy is an independent prognostic factor for poor outcome of adult ALL. No standard treatments are available for patients with MRD-positive B-precursor ALL. Blinatumomab (MT103) is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T-cell activation and a cytotoxic T-cell response against cluster of differentiation (CD)19 expressing cells. The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.

Participants will receive up to four 4-week cycles of intravenous blinatumomab treatment followed by an infusion-free period of 14 days. A safety follow-up will be performed 30 days after the end of the last infusion and efficacy follow-ups will occur until 24 months after treatment start. Participants will be followed for up to 5 years after the start of treatment for survival.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia

Keywords

  • Blinatumomab
  • MRD
  • B-ALL
  • Minimal residual disease
  • adult ALL
  • Leukemia
  • ALL
  • Lymphatic diseases
  • Lymphoproliferative disorders
  • bispecific antibody
  • anti-CD19
  • Immunotherapeutic treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with B-precursor ALL in complete hematological remission after at least 3 intense chemotherapy blocks
  • Presence of minimal residual disease at a level of ≥ 10\^-3
  • Availability of bone marrow specimen from primary diagnosis for clone-specific MRD assessment
  • Negative (HIV) test, negative (HbsAg) test and virus (anti-HCV) test
  • Negative pregnancy test in women of
  • (ECOG) performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Presence of circulating blasts or current extra-medullary involvement by ALL
  • History of relevant central nervous system (CNS) pathology or current CNS pathology
  • Prior hematopoietic stem cell transplant (HSCT)
  • Eligibility for treatment with tyrosine-kinase inhibitors (TKI)
  • Systemic cancer chemotherapy within 2 weeks prior to study treatment
  • Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment
  • Previous treatment with blinatumomab
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.

    Drug: Blinatumomab

Interventions

  • Continuous intravenous infusion

    Also known as: AMG 103, MT103, BLINCYTO™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle

    At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. Complete MRD response is defined as no polymerase chain reaction (PCR) amplification of individual rearrangements of immunoglobulin (Ig)- or T-cell receptor (TCR)-genes detected after completion of the first cycle.

    Time frame: During the first cycle (6 weeks)

Secondary outcomes

  1. Hematological Relapse-free Survival (RFS)

    Hematological RFS was measured from first dose of blinatumomab until the first assessment of documented relapse (either hematological or extramedullary), secondary leukemia, or death due to any cause. Participants without a documented relapse, or death due to any cause were censored at the time of their last hematological assessment. Participants who received chemotherapy for relapsed or persistent MRD or for any other reason after treatment with blinatumomab, or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse, or death occurred were censored at the start of chemotherapy or HSCT, respectively. Hematological relapse was defined as unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological, microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia (whichever occurred first). The 18-month Kaplan-Meier estimate of hematological RFS is reported.

    Time frame: 18 months, up to the data cut-off date of 05 August 2015

  2. Overall Survival

    Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.

    Time frame: Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.

  3. 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

    The mortality rate within 100 days after allogeneic HSCT was defined as the Kaplan-Meier estimate of the percentage of participants dying within 100 days after the day of the first allogeneic HSCT.

    Time frame: 100 days after HSCT, as of the data cut-off date of 05 August 2015

  4. Time to Hematological Relapse

    Time to hematological relapse was measured from the start of treatment with blinatumomab until hematological or extramedullary relapse. Participants who died or received HSCT or post-blinatumomab chemotherapy after treatment with blinatumomab were censored at their last hematological assessment prior to death or HSCT or post-blinatumomab chemotherapy (whichever occurred first).

    Time frame: Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.

  5. Duration of Complete MRD Response

    The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status. Participants who received chemotherapy or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse were censored at the start of chemotherapy or HSCT, respectively. MRD relapse is defined as the reappearance of individual rearrangements of Ig- or TCR-genes ≥ lower limit of quantification (LLOQ) for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4. Hematological relapse is defined as the unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological or microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia.

    Time frame: Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.

  6. Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders

    MRD level was measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory. An MRD level of 10\^-n corresponds to residual leukemia cells at a frequency of 1 per 10ⁿ bone marrow cells.

    Time frame: Baseline and end of cycle 1 (6 weeks)

  7. Number of Participants With Adverse Events

    Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.

    Time frame: From the first dose of blinatumomab until 30 days after last dose; the median treatment duration was 55 days.

  8. Change From Baseline in EORTC-QLQ-C30 Scales

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. The maximum changes from baseline to cycles 1 through 4 and the change from baseline to the end of the core study are reported.

    Time frame: Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).

  9. Change From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales

    The EQ-5D is a self-administered questionnaire which captures 3 basic types of information: a descriptive profile (health state index) and the overall health rating using a visual analog scale. The health state index measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression on scales from no problems (score = 1), some problems (score = 2), to extreme problems (score = 3). For each dimension the mean change from baseline was calculated at the end of each treatment cycle and at the end of the core study. The maximum observed change from baseline during cycles 1 to 4 and the change from baseline at the end of the core study are reported for each dimension.

    Time frame: Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).

  10. Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products

    Time frame: From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months

  11. Resource Utilization: Duration of Hospitalization

    Time frame: From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.

07

Results

Posted Feb 12, 2015

Participant flow

This study was open to adults with a diagnosis of minimal residual disease (MRD; ≥ 10-³ leukemic cells) -positive B-precursor acute lymphoblastic leukemia (ALL) who were in complete hematologic remission.

Participant flow — Overall Study
MilestoneBlinatumomab
Started116
Completed48
Not completed68
Withdrew: Death67
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle

At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. Complete MRD response is defined as no polymerase chain reaction (PCR) amplification of individual rearrangements of immunoglobulin (Ig)- or T-cell receptor (TCR)-genes detected after completion of the first cycle.

Time frame:
During the first cycle (6 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle
percentage of participantsBlinatumomab
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle77.0 (68.1 to 84.4)
SecondaryHematological Relapse-free Survival (RFS)

Hematological RFS was measured from first dose of blinatumomab until the first assessment of documented relapse (either hematological or extramedullary), secondary leukemia, or death due to any cause. Participants without a documented relapse, or death due to any cause were censored at the time of their last hematological assessment. Participants who received chemotherapy for relapsed or persistent MRD or for any other reason after treatment with blinatumomab, or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse, or death occurred were censored at the start of chemotherapy or HSCT, respectively. Hematological relapse was defined as unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological, microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia (whichever occurred first). The 18-month Kaplan-Meier estimate of hematological RFS is reported.

Time frame:
18 months, up to the data cut-off date of 05 August 2015
Reported as:
Number · percentage of participants
Hematological Relapse-free Survival (RFS)
percentage of participantsBlinatumomab
Hematological Relapse-free Survival (RFS)54 (33 to 70)
SecondaryOverall Survival

Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.

Time frame:
Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
Reported as:
Median · months
Overall Survival
monthsBlinatumomab
Overall Survival36.5 (19.2 to NA)
Secondary100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

The mortality rate within 100 days after allogeneic HSCT was defined as the Kaplan-Meier estimate of the percentage of participants dying within 100 days after the day of the first allogeneic HSCT.

Time frame:
100 days after HSCT, as of the data cut-off date of 05 August 2015
Reported as:
Number · percentage of participants
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
percentage of participantsBlinatumomab
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant7 (3 to 15)
SecondaryTime to Hematological Relapse

Time to hematological relapse was measured from the start of treatment with blinatumomab until hematological or extramedullary relapse. Participants who died or received HSCT or post-blinatumomab chemotherapy after treatment with blinatumomab were censored at their last hematological assessment prior to death or HSCT or post-blinatumomab chemotherapy (whichever occurred first).

Time frame:
Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
Reported as:
Median · months
Time to Hematological Relapse
monthsBlinatumomab
Time to Hematological RelapseNA (7.1 to NA)
SecondaryDuration of Complete MRD Response

The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status. Participants who received chemotherapy or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse were censored at the start of chemotherapy or HSCT, respectively. MRD relapse is defined as the reappearance of individual rearrangements of Ig- or TCR-genes ≥ lower limit of quantification (LLOQ) for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4. Hematological relapse is defined as the unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological or microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia.

Time frame:
Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
Reported as:
Median · months
Duration of Complete MRD Response
monthsBlinatumomab
Duration of Complete MRD Response45.0 (6.5 to 45.0)
SecondaryChange in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders

MRD level was measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory. An MRD level of 10\^-n corresponds to residual leukemia cells at a frequency of 1 per 10ⁿ bone marrow cells.

Time frame:
Baseline and end of cycle 1 (6 weeks)
Reported as:
Count of participants · Participants
Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders
ParticipantsCycle 1 MRD 10^-5Cycle 1 MRD 10^-4Cycle 1 MRD 10^-3Cycle 1 MRD 10^-2Cycle 1 MRD 10^-1Cycle 1 MRD Unknown
Baseline MRD Unknown010—00
Baseline MRD 10^-5000—00
Baseline MRD 10^-4010—00
Baseline MRD 10^-3162—10
Baseline MRD 10^-2052—10
Baseline MRD 10^-1100—02
SecondaryNumber of Participants With Adverse Events

Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.

Time frame:
From the first dose of blinatumomab until 30 days after last dose; the median treatment duration was 55 days.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsBlinatumomab
Any adverse event116
Serious adverse events73
Adverse events ≥ CTC grade 371
Adverse events ≥ CTC grade 433
Fatal adverse events2
AEs leading to discontinuation of blinatumomab20
AEs leading to interruption of blinatumomab36
Treatment-related adverse events112
Treatment-related serious adverse events60
Treatment-related adverse events ≥ CTC grade 360
Treatment-related adverse events ≥ CTC grade 426
Treatment-related fatal adverse events1
SecondaryChange From Baseline in EORTC-QLQ-C30 Scales

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. The maximum changes from baseline to cycles 1 through 4 and the change from baseline to the end of the core study are reported.

Time frame:
Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).
Reported as:
Mean · units on a scale
Change From Baseline in EORTC-QLQ-C30 Scales
units on a scaleMaximum Change From Baseline in Cycles 1 - 4Change From Baseline at End of Core Study
Global Health Status9.0 ± 4.23.9 ± 2.4
Physical Functioning2.6 ± 2.32.2 ± 1.9
Role Functioning12.2 ± 8.51.4 ± 3.5
Emotional Functioning6.5 ± 4.95.3 ± 2.7
Cognitive Functioning-3.3 ± 5.2-2.3 ± 2.5
Social Functioning12.2 ± 8.514.9 ± 3.8
Fatigue Symptom-5.9 ± 5.5-5.4 ± 2.4
Nausea and Vomiting Symptom-4.5 ± 4.7-2.3 ± 2.0
Pain Symptom3.8 ± 3.6-1.4 ± 2.7
Dyspnea Symptom-9.0 ± 4.7-0.9 ± 2.9
Insomnia Symptom-2.6 ± 3.23.7 ± 3.5
Appetite Loss Symptom-17.8 ± 6.4-9.1 ± 3.4
Constipation Symptom-5.1 ± 3.60.0 ± 2.2
Diarrhea Symptom5.1 ± 5.50.0 ± 2.3
Financial Difficulties Symptom-5.1 ± 4.8-0.9 ± 2.9
SecondaryChange From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales

The EQ-5D is a self-administered questionnaire which captures 3 basic types of information: a descriptive profile (health state index) and the overall health rating using a visual analog scale. The health state index measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression on scales from no problems (score = 1), some problems (score = 2), to extreme problems (score = 3). For each dimension the mean change from baseline was calculated at the end of each treatment cycle and at the end of the core study. The maximum observed change from baseline during cycles 1 to 4 and the change from baseline at the end of the core study are reported for each dimension.

Time frame:
Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).
Reported as:
Mean · units on a scale
Change From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales
units on a scaleMaximum Change From Baseline in Cycles 1 - 4Change From Baseline at End of Core Study
Mobility-0.2 ± 0.10.0 ± 0.1
Self-care-0.1 ± 0.10.0 ± 0.0
Usual Activities-0.1 ± 0.1-0.1 ± 0.1
Pain/Discomfort-0.2 ± 0.2-0.1 ± 0.1
Anxiety/Depression-0.2 ± 0.1-0.1 ± 0.1
SecondaryResource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products
Time frame:
From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months
Reported as:
Count of participants · Participants
Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products
ParticipantsBlinatumomab
Overall14
Cycle 15
Cycle 28
Cycle 30
Cycle 41
Follow-up period0
SecondaryResource Utilization: Duration of Hospitalization
Time frame:
From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.
Reported as:
Median · days
Resource Utilization: Duration of Hospitalization
daysBlinatumomab
Resource Utilization: Duration of Hospitalization14.0 (3 to 63)

Adverse events

Collected over All-cause mortality is reported from enrollment until the end of the follow-up period; median (minimum, maximum) time on study was 33.8 (1, 62) months. Adverse events are reported from the first dose of blinatumomab until 30 days after last dose; the median treatment duration was 55 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab67/116 (57.8%)73/116 (62.9%)111/116 (95.7%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventBlinatumomab
PyrexiaGeneral disorders17/116
TremorNervous system disorders8/116
AphasiaNervous system disorders6/116
EncephalopathyNervous system disorders6/116
NeutropeniaBlood and lymphatic system disorders5/116
OverdoseInjury, poisoning and procedural complications5/116
C-reactive protein increasedInvestigations4/116
Device related infectionInfections and infestations3/116
Staphylococcal infectionInfections and infestations3/116
SeizureNervous system disorders3/116
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBlinatumomab
PyrexiaGeneral disorders99/116
HeadacheNervous system disorders44/116
ChillsGeneral disorders30/116
TremorNervous system disorders28/116
NauseaGastrointestinal disorders27/116
FatigueGeneral disorders27/116
VomitingGastrointestinal disorders26/116
DiarrhoeaGastrointestinal disorders22/116
HypokalaemiaMetabolism and nutrition disorders18/116
InsomniaPsychiatric disorders17/116

Baseline characteristics

Full analysis set (all participants who received any infusion of blinatumomab)

Age, Continuous
Age, Continuous(years)Blinatumomab
Mean44.6 ± 16.4
Age, Customized
Age, Customized(participants)Blinatumomab
≥ 18 and <35 years36
≥ 35 and < 55 years41
≥ 55 and < 65 years24
≥ 65 years15
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab
Female48
Male68
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Blinatumomab
White102
Asian1
Mixed1
Unknown12
Philadelphia Chromosome Disease Status
Philadelphia Chromosome Disease Status(participants)Blinatumomab
Positive5
Negative111
Confirmed t(4;11) Translocation / MLL-AF4+ ALL
Confirmed t(4;11) Translocation / MLL-AF4+ ALL(Participants)Blinatumomab
Yes5
No88
Unknown23
MRD Level at Baseline by Central Laboratory
MRD Level at Baseline by Central Laboratory(participants)Blinatumomab
≥ 10^-1 and < 19
≥ 10^-2 and < 10^-145
≥ 10^-3 and < 10^-252
< 10^-33
Below Lower Limit of Quantification5
Unknown2
White Blood Cells at First Diagnosis
White Blood Cells at First Diagnosis(participants)Blinatumomab
≤ 30,000/mL78
> 30,000/mL18
Unknown20
08

Study locations

75 sites
  • 1102 - LKH Graz
    Graz, Austria
  • 1107 - Krankenhaus der Elisabethinen
    Linz, Austria
  • 1106
    Salzburg, Austria
  • 1101 - AKH Wien
    Vienna, Austria
  • 1504
    Antwerpen, Belgium
  • 1502 - Cliniques Universitaires de Saint-Luc
    Brussels, Belgium
  • 1505
    Brügge, Belgium
  • 1503
    Gent, Belgium
  • 1501 - Cliniques Universitaires UCL de Mont Godinne
    Yvoir, Belgium
  • 1211 - CHU d'Angers
    Angers, France
  • 1210 - CHU de Besançon
    Besançon, France
  • 1206 - Hôpital de Pontoise
    Cergy Pontoise, France
  • 1205 - CHU Henri Mondor
    Créteil, France
  • 1209 - CHU de Lyon
    Lyon, France
  • 1212 - Hôpital de l'hôtel Dieu
    Nantes, France
  • 1213 - Centre Hospitalier Universitaire de Nice
    Nice, France
  • 1201 - Hôpital Saint Louis
    Paris, France
  • 1202 - CHU de Bordeaux - Hôpital Haut Lévêque
    Pessac, France
  • 1208 - CHU de Purpan
    Toulouse, France
  • 1011 - Charité Berlin
    Berlin, Germany
  • 1022 - Universitätsklinkum Carl Gustav Carus Dresden
    Dresden, Germany
  • 1009 - Universitätsklinikum Essen
    Essen, Germany
  • 1002 - Klinikum der Goethe Universität
    Frankfurt, Germany
  • 1014 - Asklepiosklinik St. Georg
    Hamburg, Germany
  • 1018 - Medizinische Hochschule Hannover
    Hannover, Germany
  • 1012 - Universitätsklinikum Heidelberg
    Heidelberg, Germany
  • 1003 - Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • 1019 - Universitätsklinikum Leipzig
    Leipzig, Germany
  • 1010 - Klinikum der Universität München - Großhadern
    Munich, Germany
  • 1004 - Universitätsklinikum Münster
    Münster, Germany
  • 1016 - Universitätsklinikum Regensburg
    Regensburg, Germany
  • 1020 - Universitätsklinikum Rostock
    Rostock, Germany
  • 1007 - Robert-Bosch-Krankenhaus
    Stuttgart, Germany
  • 1015 - Universitätsklinikum Tübingen
    Tübingen, Germany
  • 1005 - Universitätsklinikum Ulm
    Ulm, Germany
  • 1001 - Julius-Maximilians-Universität Würzburg
    Würzburg, Germany
  • 1301 - Ospedali Riuniti di Bergamo
    Bergamo, Italy
  • 1303 - Istituto di Ematologia "L.& A.Seràgnoli" Azienda
    Bologna, Italy
  • 1314 - Azienda Ospedaliera Spedali Civili Brescia
    Brescia, Italy
  • 1313 - Universita di Catania
    Catania, Italy
  • 1312 - Azienda Ospedaliera Universitaria San Martino
    Genoa, Italy
  • 1305 - Ospedale San Gerardo
    Monza, Italy
  • 1309 - Azienda Ospedaliera Antonio Cardarelli
    Napoli, Italy
  • 1308 - Ospedali Riuniti "Villa Sofia-Cervello"
    Palermo, Italy
  • 1302 - Università La Sapienza di Roma
    Rome, Italy
  • 1310 - Fondazione Policlinico Tor Vergata
    Rome, Italy
  • 1315 - Azienda Ospedaliero-Universitaria S. Giovanni Battista (Le Molinette)
    Torino, Italy
  • 1311 - Azienda Ospedaliera di Verona
    Verona, Italy
  • 2204 - UMC Groningen
    Groningen, Netherlands
  • 2201 - Daniel Den Hoed Hospitaal
    Rotterdam, Netherlands
  • 1905 - Uniwersytecki Szpital Kliniczny w Białymstoku
    Bialystok, Poland
  • 1907 - Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • 1908 - Swietokrzyskie Centrum Onkologii
    Kielce, Poland
  • 1902 - Uniwersytet Medyczny w Lublinie
    Lublin, Poland
  • 1901 - Klinika Hematologii - Instytut Hematologii i Transfuzjologii
    Warsaw, Poland
  • 1906 - MTZ Clinical Research Sp. z o.o.
    Warsaw, Poland
  • 1904 - Samodzielny Publiczny
    Wrocław, Poland
  • 2101 - Institutul Clinic Fundeni, Hematologie II
    Bucharest, Romania
  • 2102 - Spitalul Clinic Coltea, Hematologie
    Bucharest, Romania
  • 2106 - Institutul Oncologic "Prof. Dr. I. Chiricuta"
    Cluj-Napoca, Romania
  • 2105 - Institutul Regional de Oncologie
    Iasi, Romania
  • 2001 - Russian Hematology Research Center
    Moscow, Russian Federation
  • 2003 - Municipal Hospital No. 15
    St. Petersburg, Russian Federation
  • 1401 - ICO Hospital Germans Trias I Pujol
    Badalona, Spain
  • 1404 - Hospital Clínic Servei d´Hematologia
    Barcelona, Spain
  • 1402 - Complexo Hospitalario Universitario A Coruña
    La Coruña, Spain
  • 1408 - Hospital 12 de Octubre
    Madrid, Spain
  • 1405 - Hospital Universitari Son Espases
    Mallorca, Spain
  • 1407 - Unidad de Citogenética Oncológica
    Salamanca, Spain
  • 1406 - Hospital Universitari i Politècnic La Fe de Valencia
    Valencia, Spain
  • 1605 - Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • 1602 - Bristol Royal Infirmary
    Bristol, United Kingdom
  • 1604 - University Hospital of Wales
    Cardiff, United Kingdom
  • 1601 - Royal Free Hospital
    London, United Kingdom
  • 1607 - Nottingham City Hospital NHS Trust
    Nottingham, United Kingdom
09

References and documents

Publications

  • Gokbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, Faul C, Bruggemann M, Taylor K, Mergen N, Reichle A, Horst HA, Havelange V, Topp MS, Bargou RC. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020 Nov;61(11):2665-2673. doi: 10.1080/10428194.2020.1780583. Epub 2020 Jul 3. PubMed 32619115 ↗
  • Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, Sridhara R, Deisseroth A, Philip R, Farrell AT, Pazdur R. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25. PubMed 30254079 ↗
  • Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Erratum In: Blood. 2019 Jun 13;133(24):2625. doi: 10.1182/blood.2019001109. PubMed 29358182 ↗
  • Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. PubMed 27209293 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Feb 2014 and a completion of Jan 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2010
First posted
Sep 22, 2010
Start
Nov 2010
Primary completionActual
Feb 2014
CompletionActual
Jan 7, 2019
Results first posted
Feb 12, 2015
Last update
Feb 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01207388
Responsible party
Sponsor
First posted
Sep 22, 2010
Start date
Nov 2010
Primary completion
Feb 2014
Completion
Jan 7, 2019
Results posted
Feb 12, 2015
Last update
Feb 10, 2020

Study contacts

Ralf Bargou, MD
principal investigator · Medizinische Klinik und Poliklinik II, Würzburg
Nicola Gökbuget, MD
principal investigator · Klinikum der Goethe Universität Frankfurt

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion